Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC

Fig. 1

The HCC-vaccine could inhibit tumorigenesis and progression. BALB/c and C57BL/6 mice were immunized with H22- or Hepa1–6- cell derived tumor vaccine once a week for three weeks. At the first week after the last immunization, BALB/c and C57BL/6 mice were inoculated subcutaneously with 2 × 106 H22 or Hepa1–6 cells, respectively. The tumor volume growth curve of tumor-bearing BALB/c (a) and C57BL/6 (c) mice were monitored. b Tumor size and tumor weight of BALB/c were detected at week 4, mice in the PBS group had all died within 4 weeks. d The survival of tumor-bearing C57BL/6 mice immunized with HCC vaccine was monitored until all the mice died. PBS, mice immunized with PBS. Lipo, Scrm, and Decoy, mice immunized with Lipo, scrambled, or Decoy-ODN-treated HCC vaccine. Data are expressed as the mean ± SD, statistical significance was determined as *p < 0.05, **p < 0.01 and ***p < 0.001 (n = 5)

Back to article page